Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Discovers Large Near Surface EM Conductor SE of Cam Copper Mine (click to learn more) Xcyte Digital Corp. Releases "Xperience" Subscription Service (click to learn more) Star Diamond: High Modelled Diamond Prices and High Proportions of Type IIa Diamonds (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News NanoViricides Inc NNVC

Healthcare Biotechnology
NanoViricides, Inc. is a development stage company, which is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Its lead drug candidate is NV-CoV-2 (API NV-387) for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. Its other... see more

Recent & Breaking News (NYSEAM:NNVC)

NanoViricides Abstract Accepted for Poster Presentation at the 2017 Annual Meeting of American Society of Virology

PR Newswire June 20, 2017

NanoViricides CEO to Present Information on Its Topical Shingles Treatment At the 2017 Marcum Investor Conference in New York City

PR Newswire June 13, 2017

NanoViricides Reports Excellent Inhibitory Effects of Its Topical Shingles Treatment Candidates Against VZV in Multiple Cell Culture Studies

PR Newswire June 6, 2017

NanoViricides Files Quarterly Report for Period Ending 2017-03-31

PR Newswire May 16, 2017

NanoViricides CEO Dr. Seymour to Present an Update on the Company at The Planet Microcap Showcase - 2017 in Las Vegas; Company Says it is Close to Declaring a Clinical Candidate for the Treatment of Shingles

PR Newswire April 26, 2017

NanoViricides Files Quarterly Report for Period Ending 2016-12-31

PR Newswire February 16, 2017

NanoViricides Reports the Company's Director Dr. Boniuk Converted Series B Debenture to Equity Effectively Raising $5M in New Equity for the Company

PR Newswire February 13, 2017

NanoViricides Publishes a Letter from the CEO to Shareholders on its Website

PR Newswire December 1, 2016

NanoViricides Files Quarterly Report for Period Ending 2016-09-30

PR Newswire November 15, 2016

NanoViricides President Dr. Diwan Gave Invited Talks on Regulatory Aspects of Nanomedicines

PR Newswire November 7, 2016

NanoViricides Signs Agreement with SUNY Upstate Medical Center for Testing of Its Drug Candidates for the Treatment of Shingles

PR Newswire October 31, 2016

NanoViricides Has Filed Annual Report, Says Company Has Sufficient Cash To Advance Into Clinical Trials

PR Newswire October 11, 2016

NanoViricides, How To Destroy A Virus, CEO Clip Video

Newsfile September 29, 2016

NanoViricides Reports on Senator Murphy's Visit to the Company's Shelton Campus

PR Newswire August 25, 2016

NanoViricides to List Common Stock on New York Stock Exchange MKT; Company Stock Symbol Will Remain NNVC

Business Wire September 23, 2013

NanoViricides Reports that its Director, Milton Boniuk, MD, Has Invested a Total of $7M in the Company this Year

Business Wire September 17, 2013

NanoViricides Reports It Has Successfully Improved HIVCide Drug Candidate in Cell Culture Studies

Business Wire September 16, 2013

NanoViricides Announces that It Has Raised approximately $10.33 Million in the Registered Direct Offering Announced Recently and Discusses Shareholder Issues since the Reverse Split

Business Wire September 12, 2013

InvestorsGuru.com 32 Filtered Mid-Day Market Movers Recap

Investors Guru September 7, 2013

NanoViricides Reports that the DengueCide(TM) Orphan Drug Application Has Been Submitted and Received by the European Medicines Agency

Business Wire September 3, 2013